EUCTR2011-003124-12-BE
Active, not recruiting
Not Applicable
A prospective phase II study on dose escalation using PET based adaptive IMRT stage II-III non small lung cancer - None
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Stage II-III Non small lung cancer
- Sponsor
- Cliniques Universitaires Saint Luc
- Status
- Active, not recruiting
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically proven NSCLC
- •Non resectable stage III or medically inoperable stage II disease when a stereotactic treatment cannot be proposed
- •No contraindication for induction or concomitant chemotherapy
- •No prior thoracic radiation
- •Moderate\-to\-good lung function with :
- •oFEV1/DLCO \= 30% of the predicted value
- •oFEV1 \= 1L
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a malignant neoplasm of the central nervous systemEUCTR2018-001404-11-ITGENENTA SCIENCE SR21
Active, not recruiting
Phase 1
A phase 1/2 study in which, DTX-SPL8783, the trial medication will beadministered (alone or in combination with nintedanib) in order to assess the safety, tolerability, pharmacokinetics (distribution of DTX-SPL8783 in the body) and efficacy in patients with advanced malignant tumours.ocally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC).MedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-000877-19-GBStarpharma Pty Ltd.65
Active, not recruiting
Phase 1
A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SN38-SPL9111 (DEP®-SN38), a SN38 dendrimer conjugate, in patients with advanced solid tumours.EUCTR2019-001318-40-GBStarpharma Pty Ltd149
Active, not recruiting
Phase 1
A phase 1/2 study in which, CTX-SPL9111, the trial medication will be administered to evaluate the safety, tolerability, pharmacokinetics (distribution of CTX-SPL9111 in the body) and efficacy in patients with advanced solid tumoursPatients with advanced solid tumoursMedDRA version: 20.0 Level: LLT Classification code 10007050 Term: Cancer System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-003424-76-GBStarpharma Pty Ltd33
Active, not recruiting
Phase 1
A Clinical Study to investigate the Safety and Tolerability of VAL201 (new trial drug) in Patients with Locally Advanced or Metastatic (cancer cells which spreads from one part of the body to another) Prostate Cancer and Other Advanced Solid Tumours.EUCTR2013-004009-25-GBValiRx plc81